BioRestorative Therapies, Inc. (BRTX)
After hours:
| Previous close | 1.6700 |
| Open | 1.7400 |
| Bid | 1.3000 x 200 |
| Ask | 2.2000 x 200 |
| Day's range | 1.7000 - 1.8300 |
| 52-week range | 1.0300 - 3.6699 |
| Volume | |
| Avg. volume | 75,380 |
| Market cap | 12.456M |
| Beta (5Y monthly) | 62.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8700 |
| Earnings date | 11 Nov 2024 - 15 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.00 |
ZacksBiorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 10.71% and 196.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireBioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the second quarter June 30, 2024 and provided an update on its business. “We have had an exciting and productive first half of 2004 and are energized by the many potential value enhancing inflection points we see ahead,” said Lance Alstod
- GlobeNewswire
BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024
MELVILLE, N.Y., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its second quarter 2024 financial results after market close on Tuesday, August 13, 2024. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Second Quarter 2024 Resul
